Literature DB >> 20357449

Malignant transformation of liver adenoma: an analysis of the literature.

Olivier Farges1, Safi Dokmak.   

Abstract

As adenoma in other locations, hepatic adenoma (HA) may transform into hepatocellular carcinoma (HCC) and hepatocyte dysplasia is most probably the intermediate step between both conditions. Malignant HA may appear as microscopic or macroscopic areas of HCC within the HA. These areas are typically well differentiated and without vascular extension or satellite nodules. AFP measurements are not reliable as they are usually normal. The risk of malignant transformation of HA cannot be reliably quantified yet. Several series are concordant to show that approximately 5% of patients whose HA have been resected had pathological evidence of HCC within their HA. This figure however does not take into account fully transformed HA where evidence of the preexisting benign lesion might have disappeared. The risk of malignant transformation is correlated with the diameter of the HA and it is very unusual when it is <5 cm and the same holds true for patients with multiple HA. These results suggest that small HA could be safely observed as they are also at low risk of bleeding. These conclusions might not apply to male patients who are at lower risk of HA, except in specific conditions, but appear to be at a much higher risk of malignant changes. Copyright 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2010        PMID: 20357449     DOI: 10.1159/000268405

Source DB:  PubMed          Journal:  Dig Surg        ISSN: 0253-4886            Impact factor:   2.588


  35 in total

Review 1.  Benign liver lesions: grey-scale and contrast-enhanced ultrasound appearances.

Authors:  A E Obaro; S M Ryan
Journal:  Ultrasound       Date:  2015-03-12

2.  Open and laparoscopic resection of hepatocellular adenoma: trends over 23 years at a specialist hepatobiliary unit.

Authors:  Nicola de'Angelis; Riccardo Memeo; Julien Calderaro; Emanuele Felli; Chady Salloum; Philippe Compagnon; Alain Luciani; Alexis Laurent; Daniel Cherqui; Daniel Azoulay
Journal:  HPB (Oxford)       Date:  2014-05-23       Impact factor: 3.647

3.  Malignant transformation of hepatocellular adenoma: how frequently does it happen?

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2015-03       Impact factor: 11.740

Review 4.  Hepatocellular adenoma management: advances but still a long way to go.

Authors:  Jean Frédéric Blanc; Nora Frulio; Laurence Chiche; Paulette Bioulac-Sage; Charles Balabaud
Journal:  Hepat Oncol       Date:  2015-05-15

Review 5.  Malignant transformation of hepatocellular adenoma.

Authors:  Christine Sempoux; Charles Balabaud; Paulette Bioulac-Sage
Journal:  Hepat Oncol       Date:  2014-12-11

6.  Guidelines for the Treatment of Hepatocellular Adenoma in the Era of Molecular Biology: An Experience-Based Surgeons' Perspective.

Authors:  Paulo Herman; Gilton Marques Fonseca; Jaime Arthur Pirola Kruger; Vagner Birk Jeismann; Fabricio Ferreira Coelho
Journal:  J Gastrointest Surg       Date:  2020-07-14       Impact factor: 3.452

Review 7.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

8.  Noncirrhotic hepatocellular carcinoma: derivation from hepatocellular adenoma? Clinicopathologic analysis.

Authors:  Ta-Chiang Liu; Neeta Vachharajani; William C Chapman; Elizabeth M Brunt
Journal:  Mod Pathol       Date:  2013-09-20       Impact factor: 7.842

9.  Extrahepatic metastasis of hepatocellular carcinoma arising from a hepatic adenoma without concurrent intrahepatic recurrence.

Authors:  N Poddar; R Ramlal; S Ravulapati; S M Devlin; S Gadani; C I Vidal; D Cao; A S Befeler; J Lai
Journal:  Curr Oncol       Date:  2017-08-31       Impact factor: 3.677

10.  Management of hepatocellular adenoma: comparison of resection, embolization and observation.

Authors:  Ami M Karkar; Laura H Tang; Nilesh D Kashikar; Mithat Gonen; Stephen B Solomon; Ronald P Dematteo; Michael I D' Angelica; Camilo Correa-Gallego; William R Jarnagin; Yuman Fong; George I Getrajdman; Peter Allen; T Peter Kingham
Journal:  HPB (Oxford)       Date:  2012-10-09       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.